Release Date: September 10, 2013
Source: R&D Center / UTop Pharma News Center
In 2013, UTop Pharma achieved a landmark technological breakthrough in peptide deep-processing: the company’s independently developed collagen peptide lyophilization protection and sublimation control system has successfully maintained over 95% bioactivity retention after freeze-drying.
This advancement not only resolves the long-standing global challenge of macromolecular peptide deactivation during lyophilization but also lays a solid foundation for the company’s strategic entry into high-value cosmetic and functional food sectors.
Collagen peptides are large, conformation-sensitive biomolecules. Conventional lyophilization processes—particularly during ice crystal formation and sublimation—often disrupt hydrogen bonding and tertiary structures, leading to peptide chain cleavage, conformational collapse, and loss of bioactive sites.
These effects significantly reduce biological activity and consistency between batches, posing a major obstacle to industrial-scale applications.
To address this challenge, UTop Pharma established a cross-disciplinary task force, adopting a dual innovation strategy focusing on both formulation optimization and process control.
Based on molecular interaction mechanisms, the team designed a protective matrix combining low-molecular-weight sugars (sucrose, trehalose), polyols (glycerol derivatives), and selected amino acid derivatives, forming a “glass-phase protection system” that stabilizes peptide chains under ultra-low temperatures.
Using Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and molecular dynamics simulations, the formulation’s protective performance on secondary and tertiary structures was validated.
The optimized formulation reduced freeze-induced stress while maintaining excellent solubility and sensory quality.
A staged temperature–vacuum profile was developed to separately optimize primary drying (free water removal) and secondary drying (bound water removal) phases.
Controlled temperature ramp rates, stable vacuum gradients, and segmented heating cycles ensured minimal ice crystal aggregation and uniform dehydration.
Process Analytical Technology (PAT) tools monitored glass transition temperature (Tg’), collapse point, and pressure in real time, achieving closed-loop control and reproducible drying curves for each batch.
During pilot-scale production, a comprehensive analytical framework—including HPLC, mass spectrometry, circular dichroism (CD) spectroscopy, and in vitro bioactivity assays—was established.
Repeated scale-up trials demonstrated moisture control within 0.8–1.2%, with consistent solubility, purity, and sensory characteristics across multiple batches.
Joint testing conducted by internal and third-party laboratories confirmed:
≥95% bioactivity retention (measured via standardized enzymatic and cell-based activity assays);
Significant reduction in batch-to-batch variability;
Improved solubility, color, and impurity profiles meeting or exceeding international quality standards.
These results verified the synergistic effectiveness of UTop Pharma’s protection formulation and sublimation control system in preserving large peptide molecules’ bioactivity.
Access to High-Value Markets:
The remarkable bioactivity retention enables UTop Pharma’s collagen peptides to serve as premium active ingredients in cosmetics and nutraceutical formulations, enhancing compatibility and efficacy validation for global brand customers.
Enhanced Product Value:
Stable, high-activity raw materials can command premium pricing and strengthen the company’s positioning as a supplier of scientifically validated bioactive peptides.
Strengthened Technological Barrier:
The reproducible, scalable nature of the process—combined with patent protection—further reinforces UTop Pharma’s competitive moat in the peptide raw material sector.
Scale-Up Production:
The company will apply this technology across expanded lyophilization lines to ensure consistent performance at industrial scale.
Product Line Diversification:
The technology platform will be extended to other sensitive bioactive peptides, including growth factor fragments and functional peptides, enriching UTop Pharma’s high-value portfolio.
Regulatory and Market Expansion:
Compliance documentation will be aligned with EU and Asia-Pacific regulatory standards, facilitating certification and long-term partnerships with global clients.
Academic Collaboration:
The R&D team will deepen cooperation with universities and third-party analytical institutions to accelerate translation from laboratory innovation to commercial application.
“Our goal has never been just to make products—but to make them better, more stable, and scientifically reliable. This breakthrough demonstrates UTop Pharma’s capability to transform advanced research into industrial-scale, high-performance bioactive ingredients.”
— Technical Director, UTop Pharma
The achievement of over 95% bioactivity retention in lyophilized collagen peptides marks a major milestone in UTop Pharma’s technological advancement journey.
It represents not only a leap in manufacturing capability but also a powerful statement of the company’s determination to elevate China’s peptide technology to the global stage.
Issued by: R&D Center
Reviewed by: Corporate Branding Department
Date: September 10, 2013
